Even more news released this week that appears to have shaken the trust for the vaccine in Americans. AstraZeneca’s Covid-19 vaccine has been ongoing on a lot of trials lately when more than a dozen countries, mostly in Europe, suspended the use of the shot over growing concerns about possible side effects.
According to the results announced on Monday, the vaccine which was developed by AstraZeneca, and the University of Oxford provided strong protection against Covid-19 in a trial involving more than 32,000 participants. The vaccine was reported to completely prevent the worst outcomes from the disease while causing no serious side effects.
This was the largest test of its kind for the vaccine. According to the results, the vaccine was 79 percent effective overall in preventing symptomatic infections. The trial showed that the vaccine offered strong protection for the elderly which has not been well-represented in earlier studies.
The news for the AstraZeneca vaccine may not make much of a difference in the U.S, where the vaccine is not yet authorized and may not be needed.
As of now, AstraZeneca is in the process of attempting to gain authorization for emergency use in the United States. If the authorization is granted will see the vaccine become available before May. Federal officials predict that the three vaccine manufacturers in the United States will be producing enough doses for all of the nation’s adults.
Even if the vaccine is not used in the United States, receiving emergency authorization from the F.D.A. — whose rigorous review process is considered the global gold standard — would be an important milestone for AstraZeneca. Some countries that have not yet authorized the vaccine may look to follow the F.D.A.’s lead.
The new results could help the vaccine recover from the scare the vaccine faced in many European countries that caused the temporary suspension of the vaccine. Regulators there initiated a safety review after a small number of people who had recently been inoculated developed blood clots and abnormal bleeding. Nonetheless, the speed at which several nations suspended the use of the vaccine reflected the fear of the vaccine and its usefulness.
Participants who received the vaccine in the trial had no increased risk of blood clots or related illnesses.
The vaccines from Pfizer and Moderna, which rely on messenger RNA technology and must be stored at very cold temperatures, were both found in large clinical trials to be about 95 percent efficacious overall in preventing symptomatic infections. Johnson & Johnson’s one-shot vaccine had a 72 percent overall efficacy rate in trial participants in the United States.